Mandate Vinge advises Vicore Pharma in connection with a directed share issue

December 04, 2018

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North. 

Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.

New assignment for Anders Leissner

Anders Leissner has been appointed by the Swedish government as chairman of the War Insurance Board.
February 26, 2021

Vinge is awarded “The Top Firm in Sweden” in WTR 1000’s latest ranking

Vinge receives the highest ranking in the World Trademark Review list of the year’s rankings. The firm obtains the Guide’s foremost ranking, which also highlights specific experts.
February 18, 2021

Insurance services in Sweden – a summary 2021

Vinge’s insurance team has written a brief summary of some of the main features of the Swedish regulations affecting foreign insurers with existing or contemplated business activities in Sweden.
February 09, 2021